FDA grants Breakthrough Therapy Designation for Xolair (omalizumab) for food allergies
- There are currently no FDA-approved treatments that help prevent severe reactions due to food allergies
- As many as 15 million Americans have food allergies ? including approximately 6 million children ? and the incidence is increasing
About Xolair
Xolair for subcutaneous use is an injectable prescription medicine approved by the FDA to treat:- Moderate to severe persistent asthma in patients six years of age or older whose asthma symptoms are not controlled by asthma medicines called inhaled corticosteroids. A skin or blood test is performed to see if a patient has allergies to year-round allergens.
- Chronic idiopathic urticaria (CIU; chronic hives without a known cause) in patients 12 years of age and older who continue to have hives that are not controlled by H1 antihistamine treatment.